Dipna Pharmachem Limited

BSE: DPL · Pharmaceuticals · sector

₹3.89BSE close 2026-10-26

Key numbers

Market cap₹10 cr

Price₹3.89

52w high / low₹20 / ₹4

P/E3.9xSector median 27.9x

P/B0.2xSector median 2.9x

Book value₹23.7

Dividend yield–Sector median 0.48%

ROE6.9%Sector median 11.7%

ROCE6.6%Sector median 12.3%

OPM3.9%Sector median 14.0%

Debt / equity0.21xSector median 0.16x

EV/EBITDA4.5xSector median 18.6x

Interest cover3.4x

Current ratio1.16x

Sales growth 3y+8.9%Sector median +9.6%

Profit growth 3y+42.5%Sector median +13.3%

PEG0.41x

Last 12 months to Mar 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1 cr vs borrowings ₹13 cr (FY26): borrowings are higher by ₹12 cr.
Operating profit covered interest 3.4x in the last 12 months.
Other income was 1% of net profit in the last 12 months.
No dividend in the last 4 financial years.
Price ₹3.89 on 2026-10-26: -81.0% from the 52-week high, 0.0% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹25.79 · low ₹3.89

Quarterly results

₹ cr	Mar 2025	Sep 2025	Mar 2026
Revenue	34	72	2
EBITDA	2	2	0
OPM %	5.7%	2.4%	21.3%
Other income	0	1	0
Net profit	1	1	0
EPS (₹)	0.27	0.59	0.07

Standalone figures where filed. Latest quarter Mar 2026.

Profit & loss (yearly)

₹ cr	FY23	FY24	FY25	FY26	TTM
Revenue	100	164	125	129	129
EBITDA	2	3	3	5	5
Net profit	1	1	1	3	3
EPS (₹)	0.76	0.90	0.41	1.00	1.00
Revenue growth		+64.5%	-24.0%	+3.3%	–
Profit growth		+19.8%	-11.0%	+171.1%	–
Dividend / share (₹)	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+8.9%	–	–
Net profit	+42.5%	–	–
EPS	+9.6%	–	–
Share price	–	-26.9% (2y)	-80.1%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	14	62
Borrowings	–	13
Cash & equivalents	0	1
Total assets	132	206
Fixed assets	0	0
Capital work in progress	–	0
Investments	0	0
Receivables	–	48
Inventory	27	42
Payables	–	110

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	-9	-18
Cash from investing	-0	-0
Cash from financing	-4	19
Capex	0	0
Free cash flow	-9	-18

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	6.7%	4.2%
ROCE %	23.8%	6.6%
Debtor days	–	136
Inventory days	88	144
Payable days	–	375
Cash conversion cycle (days)	–	-95
Working capital days	138	59

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
DPL	₹10 cr	3.9x	0.2x	6.9%	6.6%	3.9%	+8.9%	–

All 185 companies in Pharmaceuticals →

Business segments (2026-03-31)

Segment	Revenue	Share	EBIT	Margin
Chemicals Segment	₹2 cr	100.0%	₹-1 cr	-30.2%
Steel Segment	₹0 cr	–	₹1 cr	–

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	DPL
BSE code	543594
ISIN	INE0MC401013
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.